Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (October 2013)

34 slides from Sorrento Therapeutics's investor presentation, Oct 4, 2013

  1. Slide 1: Sorrento Therapeutics: Next-Generation Cancer Therapeutics

    Exhibit 99.1 Exhibit Therapeutics Sorrento Cancer Next-Generation October 99.1 2013 Therapeutics

  2. Slide 2: Safe Harbor Statement

    Safe This regarding or as Cynviloq™ presentation. Assumptions information. 2Exchange all well Harbor presentation ofasthe our risks Commission, pending will Statement The and business, inherent be contains other Company amatters review OTC information technologies including in “forward-looking fundi

  3. Slide 3: Management Team and Board of Directors

    Management Inventor Founder George CCO $430M divestitures Board David Celgene Ernst-Günther Hoechst Cam Nerveda, Kim The Henry M. Ambit Jaisim PDL Vuong Richard 3Sorrento Scott Scripps D. (former Gallagher ofWebb, of Ji, Biosciences Shah Trieu, sale Uy Janda, IgDraSol Vincent (former and of (CEO) (C

  4. Slide 4: Investment Highlights

    Investment Late Addresses Abbreviated Bioequivalence Product Therapeutic First Targeted Antibody Small Toxin Paclitaxel 4Cynviloq™ Stage antibody for Molecule launch Drug Antibody market as for multi-billion Oncology Highlights G-MAB® antibody specific regulatory Antibody drug Delivery in registrati

  5. Slide 5: Sorrento's Next-generation Cancer Therapeutics

    Sorrento’s Next-generation Cynviloq™ Bioequivalence Efficacy US High-diversity G-MAB® Lead FTO AfDC: Effective ADC: G-MAB 5Programs and and mAb Antibody Antibody EUtargets demonstrated no against include Next-Generation programs rights stacking human (BE) approved toxin Drug Abraxane® formulated het

  6. Slide 6: Pipeline

    PHASE Pipeline Metastatic }505(b)(2) Non-Small Pancreatic Bladder Ovarian INDICATION AfDC ADC G-MAB® Cynviloq™ Oncology 1H 6*Multiple 2014Cancer 2Abraxane® Strategic 1H PHASE >Cancer Breast Bioequivalence Cell VEGFR2, PD-L1, 2015 >(sNDA) Lung TARGET Cancer (BE* Partnership 3 VEGFR2, PD-1, NDA orphan

  7. Slide 7: Oncology Phase 3 Cynviloq Franchise

    Oncology Phase 7Cynviloq™ 3 Franchise

  8. Slide 8: Cynviloq: Maximum Tolerated Dose Formulation

    Cynviloq Maximum Formulation Generation Peak Taxol® 1st Cremophor 175 ~ 2nd 3rd *Analyst 8indications $1.6B Cynviloq™ Abraxane® mg/m2 Product paclitaxel (WW projection isTolerated EL the Sales inexcipient: 3rd paclitaxel nab-paclitaxel 2000) Generation ;Dose in Metastatic Polyoxyethylated polymeric

  9. Slide 9: Cynviloq Value Proposition: Exclusive Rights, Large Market

    Cynviloq 1. 2. 3. Lung 94. Exclusive Cynviloq FDA Large Cancer) concurred market is aefficacy USHigh opportunity and a.Value Available EU demonstrated Rights Proposition a. data Abraxis in support Phase (Abraxane®) pursuing 2 and Phase 505(b)(2) sold3 to studies Celgene regulatory for >pathway $3B b

  10. Slide 10: Bioequivalence: Direct and Efficient Pathway

    Bioequivalence 12 Direct Cycle Abraxane® Dose: Cmax 10 months 1260 2(90% trialmg/m2 of cost (50 CI) duration ~$5M = registration patients) Efficient Infusion (including Abraxane® time: Pathway study30 patient in min to breast Cynviloq™ Market Duration: recruitment) cancer(50 patients 3 weeks patient

  11. Slide 11: Cynviloq US Market Opportunity: Number of Patients Treated

    Cynviloq -3#~70,000 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 100,000 NSCLC Other ~55,000 15,903 Note: Sources: http://www.who.int/whosis/whosis/. represent 11 0,766 of Patients In regimens 14,479 PCMBC patients Pancreatic US treatable Market patients information, Treated Pancre

  12. Slide 12: Cynviloq Advantages

    Cynviloq™ Maximum Advantage Cynviloq Taxol® Potential 175 260 >300 Rapid Convenience Convenient No Chemical Reduced Cremophor-free q3w* Dosing q3w *Exploits donor-derived viral requirement microbial &&reconstitution: weekly = weekly** /PK side for Advantages polymer prion MBC; Tolerated storage Abra

  13. Slide 13: Potential For Cynviloq to Expand Label

    Potential For Cynviloq Best 21% Progression -2.7 Overall 6.5 2.3 High Summary: Demonstrated *Phase /advanced #13 ** 0%*** 1.5 M M** Example: Supportive unmet AUA-3-ready M*** Response Survival Invest /to Phase 4.3 Expand Free need—no San M*** 2nd clinical for New 2Care Survival development (Korea)*

  14. Slide 14: Next Steps: Bioequivalence Trial and NDA

    Next 1. 2. 3. 4. 5. Bioequivalence NDA FDA 2014 LAUNCH 14 2016 Approval: Bioequivalence NDA Product sNDA Approval Steps 2014/ Filing filing: planning launch for 2015 2015 Cynviloq 2014 Trial 2016 for (BE) /for 2016 / MBC 2015 label trial: a. expansion and Metastatic 2014 NSCLC: into Breast 2016 Blad

  15. Slide 15: Therapeutic Antibody Engine: Extensive G-MAB Pipeline

    Therapeutic Extensive G-MAB® 15 Pipeline Antibody Engine

  16. Slide 16: G-MAB Proprietary Antibody Library Technology

    -•G-MAB®: RNA Proprietary No Difficult Small Most High Size 16 AIP-4 AIP-3 AIP-2 AIP-1of Value Library Difficult Peptides Target technology Freedom-To-Operate amplification stacking Targets: Oncologyofused Antigen Targets:Therapeutic royalties Very • Fully High for Targets:2.1 high xAntibodies human

  17. Slide 17: Anti-PD-L1 Immune Modulation

    Anti-PD-L1 Immune ITumor 3000 6000 9000 12000 15000 T 200 400 600 01800 10 20 30 40 50 Competitor Day 25 *Sorrento FN-? L-2 5umor 17 ** ***Cell (pg/mL) (pg/mL) Activation Mouse Growth mAbs Modulation* mAb xenograft p<0.05, mAb mAbs Model** @ meanInhibition model(%) 0.05 Exhibit tumormg/mL using (%)

  18. Slide 18: Anti-PD-1 Immune Modulation

    Anti-PD-1 IIL-2 200 400 600 800 1000 T 5000 10000 15000 5normalized 10 15 20 25 18 0CNF-? cellConcentration Activation Concentration Sorrento ompetitor mAbmAbs to untreated mAbs (% Exhibit (pg/mL) CD25+ (pg/mL) control Potent ) Immune Modulation

  19. Slide 19: Potent Autoimmune Disease mAb

    3.5 Potent Disease mAb (EC50 Sorrento Competitor 3Untreated 219 2.5 10.5 1.5 ** 14Cell Antibody –nM) Score** 0.17 After 15 Binding Sorrento 21 17 18against 03 Experimental *Days Sorrento 16 Disease mAb mAb 19 Difficult Induction 20against 21 22 23 Auto-immune C-CGPCR Target* 24Chemokine 25 26 27 28R

  20. Slide 20: Targeted Drug ADC/AfDC Formulation Platform

    Targeted Drug ADC/AfDC 20 G-MAB®+Payload Formulation Platform

  21. Slide 21: Antibody Drug Conjugates: Components and Mechanism

    Antibody 32Key 1. 2. 3. Drug 21 Components: Potent Linker Drugconjugation ADC released binds is 54 Target-specific Cytotoxic ApoptosisConjugates cytotoxic and in 1agent ADC to receptor (cell CANCER isin internalized (ADC) death) internalizing prodrugs plasma released chemistries CELL antibody

  22. Slide 22: Anti-VEGFR2 and Anti-c-Met ADCs Demonstrate Enhanced Activity

    Anti-VEGFR2 Anti-c-Met 0(% 50 0.01 *10.001 **.0001 100 IgG of80 Leading0.1 Relative Sorrento 22 non Viability pCompetitor Cell ADCs treated value<0.0001 ADC** Viability Concentration Human 60 Human ADC 40 ADC* Demonstrate cells) 20(mAb A549 Vascular 0NSCLC 0.0001 (nM) mAb Enhanced + Toxin) Endotheli

  23. Slide 23: Anti-CXCR3 and Anti-CXCR5 ADCs Demonstrate Enhanced Activity

    Anti-CXCR3 Anti-CXCR5 Relative (% 100 = Sorrento *IgG 23 **pCells of 0. 50 Concentration non 0015**value 0Cells Cell ADC anti-GPCR naked 0.001 treated Viability ADC* ADC** expressing (mAb 0.01 mAb expressingcells) =human (nM) 0.1 ADCs pToxin + 0. Toxin) 150 100035**value human IgG Demonstrate Contro

  24. Slide 24: Antibody Drug Conjugates (AfDC) Key Features

    Antibody Key 1. 2. 3. 214. 3 Approved NoFeatures: Multiple Effective Drug TUMOR 24 internalization formulated mAbs against AfDCchemotherapeutics inTUMOR plasma / agent inbinds Cytotoxic released drug heterogeneous required Drug to combinations is Conjugates cancer with releasedtumors known antigens

  25. Slide 25: G-MAB and ADC/AfDC Pipeline

    G-MAB®, G-MAB® PD-1 VEGFR2-ADC EGFR c-Met PD-L1 CGRP CCR2 ONCOLOGY (GPCR) INFLAMMATION CXCR5 MRSA INFECTIOUS Multiple DISEASE 25 (STI-A110X) (STI-A150X) (STI-B020X) (STI-A020X) (STI-B150X) (STI-A100X) (STI-B010X) (STI-C020X) (STI-B030X) CXCR3 Strategic Antibody ADC / CCR2 (STI-A0168) and (STI-A120X)

  26. Slide 26: Positioned to Become Oncology Leader

    Positioned toPhase ADC/AfDC G-MAB® Cynviloq™ 26 Become 3 Extensive OncologyPipeline Leader G-MAB + Payload

  27. Slide 27: Small Company Valuations vs. Peers

    Small~$1.5B Company Sorrento: (Ph3/Registration Puma: MBC Clovis: NSCLC, MorphoSys: ~$2.0B ~$1.4B Pre-revenue ~$450M Seattle ImmunoGen: *ADC 27 ~$5.4B (Phase Molecule PBYI Genetics: CLVS based MBC SRNE Small Library MOR.DE 3) Product Royalty IMGN on Antibody (Phase ~$1.6B Oncology Molecule ADC SGEN

  28. Slide 28: Investment Highlights

    Investment Late ADC/AfDC G-MAB® •Cynviloq™ Addresses Stageantibody Product •Therapeutic Antibody First Oncology Highlights Abbreviated multi-billion Bioequivalence launch antibody market Drug regulatory with dollar registration in drug 1H 2016 engine >$50B in candidateExclusive pathwaypaclitaxel tri

  29. Slide 29: Financials and Capitalization

    Financials Cash Total Common Options Warrants Current IgDraSol Assignment Pro Weighted 29 Forma and Debt Capitalization Granted Outstanding Milestone Cash Stock average & $Capitalization Issuances: Agreement 5.0M Capitalization Equivalents Outstanding &exercise Outstanding 1,306,272 (2) 17,034,784 8

  30. Slide 30: Contact: Henry Ji, President and CEO

    Sorrento Henry Next-Generation Contact: PresidentTherapeutics and CEO JiCancer hji@sorrentotherapeutics.com Therapeutics (858) 668-6923

  31. Slide 31: Cynviloq Clinical Stage Trial Results

    Cynviloq Clinical Stage MBC, PC, Phase Post Total (Safety) -US p45 n=105 Cynviloq™Taxol® South 31 No =40 approval 0.03 OC, Market obvious 946 Trial 35 1Korea* 2 3NSCLC, n=104 study MTD 259 MBC Exposures pBC 30 : =Interim Patients 25 MBC, 0.001 for ethnic n=209 in United 80 105 20Abraxane® MBC 15 pRe

  32. Slide 32: Simulated Comparison of Cmax

    Simulated Comparison Cmax (ng/mL) CynviloqTM (Simulated 99.6% Abraxane® (Actual Note: Per *Cynviloq™ 32 FDA Internal Ratio 109.2% PK)* Gardner Cmax(T)/Cmax(R) requirement, PK PK) 19556 vs. (T) data AUCinf of19486 calculations Parameters mean Abraxane® and on et20324 al, file Abraxane® 22198 Ratio no

  33. Slide 33: Why Antibody Drug Conjugates

    Why Clinical Most Excellent Limited Predictable Good Effector Recruitment Tunable Engineering Targeted Antibody Hinge Feb sFc 33 region region Antibody successful serum region off-target track drug functions delivery target Drug Feb PK/PD of half characteristics record Fc Therapeutics PK patient’s C

  34. Slide 34: Top Global Therapeutic Antibodies

    TopGlobal 2012 mAb US Humira Enbrel Rituxan Remicade Herceptin Avastin Lucentis Erbitux Tysabri Xolair 34 10 Target Sales (Omalizumab) (Etanercept) Selling (Natalizumab) (Cetuximab) (Bevacizumab) (Adalimumab) (Rituximab) (Ranibizumab) (Trastuzumab) (Infliximab) Companies Therapeutic TNF EGFR CD20 Ig

Sorrento Therapeutics — Investor Presentation (October 2013) on 6ix